Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization × Clear all
NCT00049556 2013-06-20

Gefitinib in Treating Patients With Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00633750 2012-09-05

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
50 enrolled 9 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡